Treating executive dysfunction to improve insight in psychiatric disorders
Open accessAbstract
Executive dysfunction is not a primary psychiatric diagnosis in DSM 5, but it plays an important role in insight.This in turn determines treatment adherence, relapse prevention and functional improvement.This article shades light into importance of addressing executive dysfunction in treating acute mental illness, in order to improve overall outcome. Treating Executive Dysfunction to Improve Insight in Psychiatric Disorders
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A case report suggests guanfacine may be especially helpful in young adults with schizophrenia and a childhood history of abuse, and can improve insight.
“a case report by Bardoloi (2020) suggests that guanfacine may be especially helpful in young adults with schizophrenia and a childhood history of abuse, and that it can improve insight”
From Guanfacine’s mechanism of action in treating prefrontal cortical disorders: Successful translation across species (2020) · cites this paper as Bardoloi, 2018
In “Improving Executive Function to Improve Insight in Acutely Ill Psychiatric Patients” (page unavailable), the paper proposes guanfacine as a possible way to improve insight. It does not report a case or say guanfacine is especially helpful for young adults with schizophrenia and a childhood history of abuse; its discussion of insight improvement is hypothetical. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Engin Üstün, Y. (n.d.) · DergiPark (Istanbul University) · Cited by 170,090 · see citing works
Prefrontal cortex and neural mechanisms of executive function
Funahashi, S., & Andreau, J. M. (2013) · Journal of Physiology-Paris · doi:10.1016/j.jphysparis.2013.05.001 · Cited by 285 · see citing works
Hoffmann, M. W. (2013) · ISRN Neurology · doi:10.1155/2013/892459 · Cited by 90 · see citing works
Neurobiology of executive functions: Catecholamine influences on prefrontal cortical functions
Arnsten, A. F. T., & LI, B. (2004) · Biological Psychiatry · doi:10.1016/j.bps.2004.08.019 · Cited by 80 · see citing works
Neurobiology of insight deficits in schizophrenia: An fMRI study
Shad, M. U., & Keshavan, M. S. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.04.021 · Cited by 52 · see citing works
Editorial: Executive Functions in Psychiatric Disorders
Malloy‐Diniz, L. F., de Miranda, D. M., & Grassi‐Oliveira, R. (2017) · Frontiers in Psychology · doi:10.3389/fpsyg.2017.01461 · Cited by 30 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- Rabinovici G, Stephens M, Possin K. Executive [1] dysfunction. CONTINUUM: Lifelong Learning in Neurology. 2015; 21(3, Behavioral Neurology and Neuropsychiatry): 646-659. http://ovidsp. ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC =Y&PAGE=fulltext&D=ovft&AN=00132979- 201506000-00011. doi: 10.1212/01.CON.0000 466658.05156. · DOI
- of cognitive disorders: A century of discoveries at yale. The Yale journal of biology and medicine. 2012; 85(1): 45-58. https://www.ncbi.nlm.nih. gov/pubmed/22461743.
Cited by
Sorted by citations
Arnsten, A. F. T. (2020) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2020.107327 · Cited by 75 · see citing works
“However, a case report by Bardoloi (2020) suggests that guanfacine may be especially helpful in young adults with schizophrenia and a childhood history of abuse, and that it can improve insight, and thus have global benefits (Bardoloi, 2018).”
- Authors
- Sarma Bardoloi, P.
- Venue
- Archives of Neurology and Neuro Disorders
- Publisher
- Sryahwa Publications
- Published
- 2018
- Volume
- 1
- Issue
- 2
- Pages
- 27-30
- ISSN
- 2638-504X (ISSN-L)
- OpenAlex
- W4327512046
- Cited by
- 1
- References
- 5
- Citations by year
- 2020: 1
- FWCI
- 0.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Archives of Neurology and Neuro Disorders (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Life Sciences › Neuroscience › Cognitive Neuroscience › Neural and Behavioral Psychology Studies
- Keywords
- executive dysfunction, insight, mental illness, medication adherence, relapse prevention, functional outcome, acute mental illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
